☆ 4.6 Editorial Material

Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study

W. Gulliver et al.

Summary: The study found that patients with moderate and high AN counts achieved better results at 24 and 52 weeks of treatment with adalimumab, with gender and age at onset affecting treatment effectiveness. The use of adalimumab led to a decrease in lesions, especially in inflammatory nodules, and the IHS4 scores of responders were substantially lowered. No new safety issues were detected during the treatment and observation period.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Article Dermatology

Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data

John W. Frew et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

添加到收藏夹

Article Dermatology

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity

C. C. Zouboulis et al.

BRITISH JOURNAL OF DERMATOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Alexa B. Kimball et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa

相关参考文献

Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study

Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

导出引文

分享论文